CRISPR 'Smart Bomb' Aims to Disarm Superbugs in Landmark Human Trial

COPENHAGEN, Denmark – March 03, 2026 – A new frontier in the war against antibiotic resistance is opening, powered by the gene-editing tool CRISPR. Danish biotech firm SNIPR Biome has announced a significant milestone with the publication of final Phase 1 clinical trial results for its pioneering therapeutic, SNIPR001, in the prestigious journal The Lancet Microbe. The study validates the safety and targeted action of the first-ever orally administered CRISPR-based drug in humans, offering a potential paradigm shift in how we combat deadly bacterial infections.

SNIPR001 is designed as a precision weapon against Escherichia coli (E. coli), a common bacterium that can cause life-threatening bloodstream infections, particularly in vulnerable patients. Unlike traditional broad-spectrum antibiotics that cause widespread collateral damage to the body's beneficial bacteria, SNIPR001 is engineered to selectively hunt and destroy its target, including strains that have developed resistance to conventional drugs.

A New Era of Precision Antimicrobials

At the heart of SNIPR001 is a novel technology that combines two natural biological systems: bacteriophages and CRISPR-Cas. Bacteriophages, or "phages," are viruses that have evolved to infect and kill specific bacteria. SNIPR Biome has engineered a cocktail of four distinct phages to act as delivery vehicles, arming them with a CRISPR-Cas system programmed to act as a molecular "smart bomb."

Once administered orally, these phages navigate the complex environment of the human gut and specifically attach to E. coli cells. Upon injection of their genetic payload, the CRISPR-Cas system activates, seeking out and cutting the E. coli's own DNA at multiple critical locations. This targeted shredding of the bacterial genome ensures the pathogen is killed, preventing it from multiplying and causing infection.

This approach marks a radical departure from the last century of antibiotic development. Broad-spectrum antibiotics, while life-saving, function like a sledgehammer, wiping out both harmful pathogens and the vast communities of beneficial microbes that are essential for digestion, immune function, and overall health. This disruption can lead to secondary infections and further fuels the global crisis of antimicrobial resistance (AMR). SNIPR001, by contrast, acts as a scalpel, precisely removing the threat while leaving the delicate gut microbiome intact.

"Having the final Phase 1 results published in The Lancet Microbe is a major milestone for SNIPR and an important validation of our scientific approach," commented Eric van der Helm PhD, Head of Business Development. "We believe this is a true validation of CRISPR-enabled medicine as a precision approach to tackling antibiotic-resistant bacteria.”

Validating Safety and Precision in Humans

The first-in-human Phase 1 trial (NCT05277350) was a randomized, double-blind, placebo-controlled study conducted in 36 healthy volunteers. The primary goal was to assess the safety and tolerability of SNIPR001, which was administered orally twice daily for seven days across three different dose levels.

The results published in The Lancet Microbe demonstrated a favorable safety profile. There were no serious adverse events reported in the groups receiving SNIPR001, and the number of overall adverse events was comparable to the placebo group.

Crucially, the study confirmed the therapy's precision and targeted action. Functional SNIPR001 was recovered from stool samples in a dose-proportional manner, indicating it successfully transited the gastrointestinal tract. Meanwhile, it was not meaningfully detected in blood or urine, confirming that the therapy remains contained within the gut as intended. Furthermore, analysis of the gut microbiota showed its composition remained stable and did not significantly differ between the treatment and placebo groups, validating the drug's microbiome-sparing design.

While the study was not powered to measure efficacy, it did show a promising pharmacodynamic signal. The highest dose group showed a 78% reduction in E. coli levels in the gut compared to placebo at day 14, hinting at the therapeutic's potential to effectively decolonize the gut of this specific pathogen.

A Lifeline for Vulnerable Cancer Patients

The initial focus for SNIPR001 is on one of the most vulnerable patient populations: individuals with hematological cancers, such as leukemia and lymphoma, who are undergoing hematopoietic stem-cell transplantation (HSCT). These patients have their immune systems deliberately suppressed by chemotherapy, making them extremely susceptible to infections.

For them, E. coli residing in their own gut can become a deadly threat. The bacteria can translocate from the compromised gut into the bloodstream, causing severe infections that are a leading cause of morbidity and mortality. Annually, an estimated 35,000 such life-threatening E. coli infections occur in the United States and Europe among this patient group.

The current standard of care involves pre-emptive treatment with broad-spectrum antibiotics like fluoroquinolones. However, rising rates of antibiotic resistance often render these drugs ineffective, and their use further damages the patient's already fragile gut microbiome. This creates a critical unmet need for a targeted preventative strategy, a role SNIPR001 is designed to fill. In recognition of this, the U.S. Food and Drug Administration (FDA) has granted SNIPR001 Fast-Track designation to expedite its development and review.

Advancing Toward a Critical Unmet Need

Building on the positive Phase 1 data, SNIPR Biome is now evaluating the therapy in its intended patient population. The company announced that its ongoing Phase 1b clinical trial (NCT06938867) in hematological cancer patients is now more than halfway through its recruitment target of 24 patients. The randomized, double-blind, placebo-controlled study is being conducted at eight leading cancer centers across the United States.

"Building on these Phase 1 results, we are focused on advancing SNIPR001 in the patient population where the need is greatest," said Dr. med. Christian Grøndahl, CEO and Co-founder of SNIPR. "This study is an important next step toward evaluating SNIPR001’s potential to reduce the risk of E. coli bloodstream infections in vulnerable patients undergoing stem-cell transplantation, and we look forward to progressing the program as recruitment continues.”

The development of SNIPR001 is backed by a global consortium dedicated to fighting antimicrobial resistance, including CARB-X, Wellcome, and Germany's Federal Ministry of Research, Technology and Space. This support underscores the international importance placed on finding novel solutions to the growing superbug crisis. The success of SNIPR001 not only offers hope for a single product but also validates SNIPR Biome’s entire CRISPR-based therapeutic platform, which is being expanded to target other dangerous pathogens like Klebsiella pneumoniae and Pseudomonas aeruginosa in partnership with organizations like the Bill & Melinda Gates Foundation and the Cystic Fibrosis Foundation. As the clinical program progresses, the medical community watches closely to see if this precision tool can finally turn the tide in the fight against resistant infections.